Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 15, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice of Basic Agreement on Capital and Business Alliance with Callisto Inc.

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President and CEO; Securities Code: 197A; hereinafter "the Company") hereby announces that it has reached a basic agreement with Calisto Inc. (Head Office: Shinjuku-ku, Tokyo; CEO Changhee Han; hereinafter "Calisto"), under which TAUNS will subscribe to newly issued common shares of Calisto and the two companies will pursue a business alliance aimed at building a healthcare data utilization platform.

1. Background and Purpose of the Business Alliance

By combining Callisto's technologies and business foundation for the acquisition, processing and analysis of medical data with TAUNS' diagnostic technologies and network of medical institutions, the companies will promote the development of a medical data bank in which clinical information, including specimen information, medical images and electronic medical records, is organized and integrated in a form that is easy to use for research and development, while complying with applicable laws and regulations and giving due consideration to ethics and information security.

In addition, the companies will develop an operational environment that supports the advanced utilization of medical data, including computing resources and AI analysis environments.

Through these initiatives, the two companies aim to contribute to the creation of new value through the utilization of medical data and to the resolution of social issues.

2. Overview of Calisto Inc.

(1) Name	Callisto Inc.
(2) Location	18F Shinjuku Sumitomo Building, 2-6-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan
(3) Title and name of representative	Changhee Han, CEO
(4) Business	①Building medical imaging data infrastructure for medical AI and clinical research ②Custom development and technical consulting for AI-driven drug discovery and medical AI
(5) Date of establishment	June 27, 2022
(6) Corporate site	https://callisto-en.com

3. Comments from Both Companies

<u>Comment from Masaki Nonaka, President and CEO of TAUNS Laboratories, Inc.</u>

"Under our Mid-Term Management Plan, we have set forth the development of a medical data and AI platform.

We are very pleased to be able to create value together through the utilization of medical data by advancing this alliance with Callisto. Callisto has a high level of expertise and extensive experience in the acquisition, processing and analysis of medical data, and we believe it is an extremely important partner in promoting the utilization of medical data.

By further deepening collaboration that leverages the strengths of both companies, we will continue to contribute to resolving issues in medical settings through the utilization of medical data."

<u>Comment from Changhee Han, CEO of Callisto Inc.</u>

We sincerely appreciate TAUNS' investment in recognition of our technological capabilities, medical data assets and customer track record as we seek to build medical image data infrastructure that supports the era of medical AI and drug discovery AI.

By combining the medical institution and customer networks that the TAUNS Group has cultivated through its specimen testing business and other activities, its commercialization foundation including pharmaceutical affairs and distribution, and its computing resources with our technologies and resources related to medical data, we will accelerate expansion into the pharmaceutical field and overseas markets.

Japan, one of the world's most advanced aging societies and a country with a universal health insurance system, has accumulated a vast amount of diverse and high-quality medical data, including radiological images, pathology images, clinical information, specimen information and molecular data.

To date, we have collaborated with medical institutions in Japan to build medical image datasets and have provided them to approximately 20 pharmaceutical companies, medical device manufacturers, medical AI companies and academic institutions in Japan, the United States, Europe and South Korea.

By advancing this business alliance, we will build a large-scale, multimodal medical data platform and AI analysis platform that enable cross-sectional utilization of medical images, clinical information, molecular data and biobank specimens, and contribute to more accurate and earlier diagnosis and treatment, optimization of medical costs, and extension of healthy life expectancy around the world."

4. Outlook

At this time, the Company believes that the impact of this basic agreement on its near-term financial results will be limited. Should any material impact become evident, the Company will promptly disclose such information.

5. Other Matters

Certain details of this basic agreement have not been disclosed based on mutual agreement between the parties.